文献速递特殊人群用药治疗药物监测与药物基因组学

妊娠与哺乳期贝达喹啉暴露:耐药结核女性的药代动力学研究

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis.
PubMed 文献 · Br J Clin Pharmacol · 2022-05-26

本研究纵向评估妊娠对贝达喹啉药代动力学的影响,并首次描述哺乳期母乳中贝达喹啉暴露。13名HIV阳性耐利福平结核孕妇入组,6名完成产前产后采样;妊娠期及产后贝达喹啉暴露均低于非妊娠对照,母乳浓度显著高于母体血浆(乳/浆比14:1),母乳喂养婴儿剂量与母体相当。

要点

  • 妊娠期及产后贝达喹啉暴露低于非妊娠对照,需关注剂量不足风险
  • 贝达喹啉在母乳中显著蓄积,乳/母血浆浓度比达14:1
  • 母乳喂养婴儿贝达喹啉mg/kg剂量与母体剂量相当

核心结论

  • 耐利福平结核孕妇中贝达喹啉暴露低,且药物在母乳中显著蓄积,母乳喂养婴儿可达到与母体相当的mg/kg剂量。

研究设计与样本

  • 纵向药代动力学研究,入组13名接受耐利福平结核治疗的孕妇,其中6名完成妊娠晚期与产后约6周的药代动力学采样。
  • 妊娠晚期和产后各进行4个时间点、覆盖6小时的药代动力学采样,并采集哺乳母亲系列母乳样本及婴儿单次血浆样本。

主要发现

  • 所有参与者均为HIV阳性并接受抗逆转录病毒治疗。
  • 妊娠晚期和产后贝达喹啉暴露均低于已报道的非妊娠对照。
  • 母乳中贝达喹啉浓度高于母体血浆,乳/母血浆比为14:1。
  • 4名婴儿(中位年龄6.5周)有单次随机血浆贝达喹啉及M2浓度:1名母乳喂养婴儿浓度与母体血浆相似,3名非母乳喂养婴儿浓度可检测但低于母体血浆。

临床怎么用

  • 对耐利福平结核孕妇应关注贝达喹啉暴露不足的可能,并考虑治疗药物监测。
  • 哺乳期使用贝达喹啉时需评估母乳喂养婴儿的暴露风险。

局限性

  • 样本量小,仅6名完成产前产后药代动力学采样。
  • 婴儿血浆样本为单次随机采样,且仅4名婴儿有可用浓度数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We aimed to explore the effect of pregnancy on bedaquiline pharmacokinetics (PK) and describe bedaquiline exposure in the breast milk of mothers treated for rifampicin-resistant tuberculosis (TB), where there are no human data available. METHODS: We performed a longitudinal PK study in pregnant women treated for rifampicin-resistant TB to explore the effect of pregnancy on bedaquiline exposure. Pharmacokinetic sampling was performed at 4 time-points over 6 hours in the third trimester, and again at approximately 6 weeks postpartum. We obtained serial breast milk samples from breastfeeding mothers, and a single plasma sample taken from breastfed and nonbreastfed infants to assess bedaquiline exposure. We used liquid chromatography-tandem mass spectrometry to perform the breast milk and plasma bedaquiline assays, and population PK modelling to interpret the bedaquiline concentrations. RESULTS: We recruited 13 women, 6 of whom completed the ante- and postpartum PK sampling. All participants were HIV-positive on antiretroviral therapy. We observed lower ante- and postpartum bedaquiline exposures than reported in nonpregnant controls. Bedaquiline concentrations in breast milk were higher than maternal plasma (milk to maternal plasma ratio: 14:1). A single random plasma bedaquiline and M2 concentration was available in 4 infants (median age: 6.5 wk): concentrations in the 1 breastfed infant were similar to maternal plasma concentrations; concentrations in the 3 nonbreastfed infants were detectable but lower than maternal plasma concentrations. CONCLUSION: We report low exposure of bedaquiline in pregnant women treated for rifampicin-resistant TB. Bedaquiline significantly accumulates in breast milk; breastfed infants receive mg/kg doses of bedaquiline equivalent to maternal doses.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Court R, Gausi K, Mkhize B, et al. Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. Br J Clin Pharmacol. 2022. PMID: 35526837. doi:10.1111/bcp.15380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。